European Journal of Haematology

Article	Citations
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect	89
	53
	49
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma	45
Issue Information	43
Vaccination in Multiple Myeloma: Challenges and Strategies	39
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial	33
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	33
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study	27
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway	27
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma	25
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation	24
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia	23
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma	23
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia	22
Issue Information	22
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning	21
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	21
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy	19
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea	18
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes	18
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes	18
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia	17
	17
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States	17

The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review	17
Are we ready for personalizedCAR‐Ttherapy?	17
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	16
Soluble MIC‐A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma	16
Transfusion requirements and complication rate in β‐thalassemia intermedia due to heterozygous β‐globin gene mutation and triplicated α‐globin genes	16
Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma	16
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study	15
Construction of Lymphoma Organoids and Applications in Tumor Microenvironment Research	15
Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients	15
From Rh Blood Group Antigen Antibody Testing to “Transfusionomics”	14
Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry	14
Issue Information	14
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine	13
Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review	13
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	13
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	13
The Amyloidosis Intersection: Dual Amyloid Types in a Single Host	13
Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal t	13
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia	13
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy	12
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis	12
	12
Hematological and genetic profiles of persons with co‐inherited heterozygous β‐thalassemia and supernumerary α‐globin genes	12
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	12
Home‐Based Daratumumab in Patients With Multiple Myeloma	12
Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross‐Sectional Survey	11
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population	11
Outcomes of COVID‐19 hospitalizations in patients with sickle cell disease: A nationwide analysis	11
Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma	11
Persistent decreased bone marrow CD3+CD56+ T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes	11
Issue Information	11
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients	11
Sequencing and combination of currentsmall‐moleculeinhibitors for chronic lymphocytic leukemia: Where is the evidence?	10
A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	10
Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management	10
Issue Information	10
Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation	10
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis	10
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based GVHD	10
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program	10
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia	10
Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia	9
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial	9
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study	9
The incidence, complications, and treatment of iron deficiency in pregnancy	9
Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma	9
Global prevalence of anemia among women of reproductive age, 2000–2019	9
Long‐term haematological response and maintained immunological function after laparoscopic subtotal splenectomy in patients with hereditary spherocytosis	9
	9
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma	9

Three cases of late‐onset post CAR‐T therapy isolated CNS relapse in R/R large B‐cell lymphoma	9
Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study	9
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study	9
	9
Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists	9
	9
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition	9
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study	8
	8
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir‐exposed CMV‐free population receiving PTCy	8
Interferon gamma regulates a complex pro‐survival signal network in chronic lymphocytic leukemia	8
Development and validation of the sickle cell stress scale‐adult	8
Phenotype of BTK‐lacking myeloid cells during prolonged COVID‐19 and upon convalescent plasma	8
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	8
A precision‐based exercise program for patients with multiple myeloma	8
CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T‐Cell Acute Lymphoblastic Leukemia	8
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors	8
Clinical outcomes of patients referred for asymptomatic neutropenia: A focus on racial disparities in hematology	8
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on theEORTC‐Dutchlate effects cohort‐linked data	8
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges	8
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study	8
Chimeric antigen receptor T cells for acute myeloid leukemia	8
ProGraME: A novel flow cytometry algorithm for the diagnosis of low‐risk myelodysplastic syndromes in patients with cytopenia	8
	8
Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group	8
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients	7
Issue Information	7
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review	7
Screening for multidrug‐resistant organisms in high‐risk hospitalized patients with hematologic diseases	7
Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (	7
Clinical Management of Persistent Hypereosinophilia	7
Optimizing Pediatric Tunneled Central Venous Catheter Placement: A Height‐Based Approach for Precise Length Determination	7
Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of	7
Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)	7
Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital	7
	7
ABO Blood Type and Short‐Term Mortality in Patients With Infection‐Associated Disseminated Intravascular Coagulation	7
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	7
Issue Information	7
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management	7
The applicability of the central line‐associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients	7
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	7
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning	7
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents	7
Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis	7
Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study	7
Treatment of Refractory Monoclonal Immunoglobulin Deposition Disease With BCMA Bispecific Antibody	7
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study	7
Fetal Hemoglobin Decrease During Voxelotor Treatment	7
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis	7
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms	7
Re‐evaluation of rituximab therapy for idiopathic Castleman disease: Retrospective study from single‐center experience	7
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review	7
Trends and in‐hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002–2019)	7
Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023	7
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups	6
	6
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care	6
Insulin‐like growth factor‐1 and insulin‐like growth factor binding protein‐3: impact on early haematopoietic reconstitution following allogeneic haematopoietic stem cell transplantation	6
Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia	6
Issue Information	6
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study	6
Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemoth	6
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry	6
A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	6
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy	6
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review	6
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients	6
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center	6
The role of oral iron in the treatment of adults with iron deficiency	6
The current challenges faced by people with hemophilia B	6
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology	6
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents	6
Core Needle Biopsies in Patients With Lymphoproliferative Malignancies: An Observational Single‐Center Cohort Study	6
Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients	6
Busulfan and cyclophosphamide‐based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion‐dependent thalassem	6
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose	6
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients	6
Cytogenetic and molecular characteristics and outcomes of adult patients with early T‐cell precursor acute lymphoblastic leukemia	6
The impact of hematology electronic consultations on the management of iron deficiency	6

Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults	6
Effectiveness of progressive moderate‐vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: Secondary analysis of a randomized	6
Recombinant factor IX Fc for the treatment of hemophilia B	6
Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study	6
The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives	6
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis	6
Featured Cover	6
Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the p	6
Clonal Progression and Leukemic Transformation of a TP53 Mutated Post‐Polycythaemia Vera Myelofibrosis	6
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	6
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients fr	5
Apheresis collection of mononuclear cells for chimeric‐antigen receptor therapies	5
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders	5
ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B	5
	5
Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation	5
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic	5
Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD‐SIQ)	5
LP2, a stable lanthipeptide derived from cAng‐(1‐7), exerts myeloprotective action in mice	5
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	5
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	5
Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease	5
Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia	5
Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study	5
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	5
CLLAF SCORE—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive CLL Patients Initiating First‐ and Second‐Generation BTK Inhibitor Therapy	5
Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecula	5
Treatment horizon in multiple myeloma	5
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies	5
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients	5
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database	5
	5
Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas	5
Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia	5
Issue Information	5
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients	5
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation	5
Marked hyperferritinemia in critically ill cancer patients	5
Differences in patient‐reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis	5
Real‐World Evidence of Crizanlizumab Showing Reductions in Vaso‐Occlusive Crises and Opioid Usage in Sickle Cell Disease	5
Issue Information	5
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	5
	5
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	5
Assessing the Burden of C5 Inhibitor Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria	5
Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen	5
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls	5
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings	5
Biological Findings and Clinical Outcomes in Patients Treated With R‐CHOP Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement	5
Further Reflections on 6‐MP Adherence and Habit Strength: The Impact of Dose Adjustment Complexity and Caregiver Burden	5
Iron Deficiency in the Presence of Anemia and Inflammation—A Sex‐Specific Cross‐Sectional Study	5
Issue Information	5
Cytokine expression in pediatric patients with immune thrombocytopenia (ITP) in different phases of disease	5
The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands	5
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review	5
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study	5
Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia	5
Correction to “Venetoclax‐Based Therapy for Relapsed or Refractory Acute Myeloid Leukaemia Following Intensive Induction Chemotherapy”	5
Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy	5
Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study	5
A New Strategy for Adult T‐Cell Leukemia Treatment Targeting Glycogen Synthase Kinase‐3β	5
Effects of anti‐Xa activity monitoring on the outcome of high‐risk pregnancies treated with a prophylactic dose of low‐molecular‐weight heparin	5
Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey	5
Childhood autoimmune hemolytic anemia: A scoping review	5
Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia	5
Relationship between pancreatic iron overload, glucose metabolism and cardiac complications in sickle cell disease: An Italian multicentre study	4
Central Nervous System Manifestations of Graft‐Versus‐Host Disease	4
Late transplant‐associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections	4
Issue Information	4
Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation	4
Molecular pharmacology in complement‐mediated hemolytic disorders	4
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study	4
Time to pain relief: A randomized controlled trial in the emergency department during vaso‐occlusive episodes in sickle cell disease	4
Hydroxyurea at escalated dose versus fixed low‐dose hydroxyurea in adults with sickle cell disease	4
Ten‐year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program	4
Splenic Embolization in Refractory Immune Thrombocytopenia	4
Low‐dose rituximab plus high‐dose dexamethasone in newly diagnosed immune thrombocytopenia	4
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience	4
Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study	4
Chronic kidney disease and outcomes in hospitalized sickle cell disease patients: A National Inpatient Sample analysis	4
Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement	4
Auer rods and faggot cells: A review of the history, significance and mimics of two morphological curiosities of enduring relevance	4
Long‐term progression‐free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons	4
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning	4
Upregulation of microRNA‐597 in myelodysplastic syndromes induces apoptosis through FOSL2 inhibition	4
Treatment‐Free Remission in Chronic Myeloid Leukemia: Revisiting the “W” Questions	4
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain	4
Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK	4
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma	4
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients	4
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma	4
Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study	4
Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine	4
Progressive multifocal leukoencephalopathy in multiple myeloma	4
Clinical Relevance and Prognostic Value of the Triple A (AAA) Score in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX)	4